Featured Speakers Include:

  • Dr. Eric J. Niesor
    Head Dyslipidemia Research, Metabolic Disease Biology Area, Roche (Switzerland)
  • Dr. Sanjay Bhanot
    Metabolic Franchise Leader, VP, Metabolic Disorders and Translational Medicine, Isis Pharmaceuticals
  • Dr. Allan Ertmann Karlsen
    VP, Diabetes Biology, Novo Nordisk (Denmark)
  • Professor Peter J. Havel
    Department of Molecular Biosciences, School of Veterinary Medicine and Department of Nutrition, University of California
    Davis
  • Dr. James F. List
    Group Director, Cardiovascular and Metabolics, Bristol-Myers Squibb

Groundbreaking Advances and Key Opinions in Metabolic Diseases Drug Discovery and Development

IQPC’s Metabolic Diseases Program is designed to bring together valuable case studies, lessons learned and best practices in the forms of panel session in drug discovery and development. The specific focuses of the program include:

  • Adapting the new cardiovascular study requirement for diabetic drugs – where do you start or should you abandon it?
  • Inflammation aspects of metabolic diseases
  • Comparing and contrasting clinical models and selecting the best

This event gives you the chance to hear from your peers who are faced with the same challenges but are seeking innovative approaches. Meet colleagues who have come up with unique compounds and who have taking steps to measure the ROI of their drug development process.

Highlights of this Program Include:

  • Understanding the evolving regulatory environment for metabolic development
  • SGLT2 Inhibition: a novel approach to the treatment of type 2 diabetes
  • Introducing integrated neurohormonal therapy for obesity (INTO)
  • Exploring recent discovery in FGF21 receptor interaction and activation mechanism
  • Uncovering new therapeutic approaches - de-stressing metabolic disease
  • Targeting adipose vasculature for new anti-obesity therapeutics
  • Discovery of PF-04620110: a selective DGAT-1 Inhibitor for the treatment of type 2 diabetes

Advisory Board Committee

  • Dr. Wick Johnson, Senior Director, Worldwide Business Development, Pfizer
  • Dr. Mike Cawthorne, Director of Metabolic Research, Clore Laboratory, University of Buckingham
  • Dr. Jon Arch, Professorial Research Fellow & Deputy Director, Metabolic Research, University of Buckingham
  • Dr. Andrew Swick, Director, Cardiovascular & Metabolic Diseases, Pfizer Global R&D
  • Dr. Timothy Herpin, Director, Bristol-Myers Squibb
  • Dr. Ming Wang, Scientific Director, Metabolic Disorders Research, Amgen

Sponsor
Sponsors and Exhibitors

[ Register Now ]